Arch Biopartners expands Phase II LSALT peptide trial for cardiac surgery-related acute kidney injury to US

• Arch Biopartners will expand its Phase II LSALT peptide trial in cardiac surgery-associated acute kidney injury into the United States.
• Interim results have not been presented; additional updates are expected as U.S. sites begin recruiting and dosing patients.
• Management cited clinician interest at five U.S. institutions, aiming to broaden access to eligible patients and sustain enrollment momentum.
• Early trial conduct to date showed no study drug-related adverse events, supporting continued development and a larger site footprint.
• New U.S. sites are expected to take about four to six months to complete start-up work before treating their first patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arch Biopartners Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110744PRIMZONEFULLFEED9807648) on August 11, 2026, and is solely responsible for the information contained therein.